Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults

Summary

The objective is to assess the humoral and cellular immune response of the VAX102 vaccine delivered IM and SC in a prime-boost regimen at dose levels 1 µg or 2 µg in healthy adults against the influenza A virus M2e antigen after each vaccination.

Timeline

Start

2009-06

Primary completion

2009-10

Completion

2009-12

Drugs

Indications